Compositions of a cyclooxygenase-2 selective inhibitor and a calcium modulating agent for the treatment of pain, inflammation or inflammation mediated disorders
AssigneePharmacia Corporation
InventorsDiane Stephenson, Duncan Taylor
Life of this patent
Estimating the term…
Abstract
The present invention provides compositions and methods for the treatment of pain, inflammation or inflammation mediated disorders in a subject. More particularly, the invention provides a combination therapy for the treatment of pain, inflammation or inflammation mediated disorders comprising the administration to a subject of a calcium modulating agent in combination with a cyclooxygenase-2 selective inhibitor.
Claims37
A method of treating pain, inflammation or an inflammation mediated disorder, the method comprising:
- (a) diagnosing a subject in need of treatment for pain, inflammation or an inflammation mediated disorder;
- and
- (b) administering to the subject a cyclooxygenase-2 selective inhibitor or an isomer, a pharmaceutically acceptable salt, ester, or prodrug thereof and a calcium modulating agent or an isomer, a pharmaceutically acceptable salt, ester, or prodrug thereof.
A method of treating pain, inflammation or an inflammation mediated disorder, the method comprising:
- (a) diagnosing a subject in need of treatment for pain, inflammation or an inflammation mediated disorder;
- and
- (b) administering to the subject a calcium modulating agent or an isomer, a pharmaceutically acceptable salt, ester, or prodrug thereof and a cyclooxygenase-2 selective inhibitor or an isomer, a pharmaceutically acceptable salt, ester, or prodrug thereof, wherein the cyclooxygenase-2 selective inhibitor is a chromene compound, the chromene compound comprising a benzothiopyran, a dihydroquinoline or a dihydronaphthalene.
A method of treating pain, inflammation or an inflammation mediated disorder, the method comprising:
- (a) diagnosing a subject in need of treatment for pain, inflammation or an inflammation mediated disorder;
- and
- (b) administering to the subject a calcium modulating agent or an isomer, a pharmaceutically acceptable salt, ester, or prodrug thereof and a cyclooxygenase-2 selective inhibitor or an isomer, a pharmaceutically acceptable salt, ester, or prodrug thereof, wherein the cyclooxygenase-2 selective inhibitor is a tricyclic compound, the tricyclic compound comprising a benzenesulfonamide or methylsulfonylbenzene.
A method of treating pain, inflammation or an inflammation mediated disorder, the method comprising:
- (a) diagnosing a subject in need of treatment for pain, inflammation or an inflammation mediated disorder;
- and
- (b) administering to the subject a calcium modulating agent or an isomer, a pharmaceutically acceptable salt, ester, or prodrug thereof and a cyclooxygenase-2 selective inhibitor or an isomer, a pharmaceutically acceptable salt, ester, or prodrug thereof, wherein the cyclooxygenase-2 selective inhibitor is a phenyl acetic acid compound.
A method of treating pain, inflammation or an inflammation mediated disorder, the method comprising:
- (a) diagnosing a subject in need of treatment for pain, inflammation or an inflammation mediated disorder;
- and
- (b) administering to the subject a cyclooxygenase-2 selective inhibitor selected from the group consisting of celecoxib, deracoxib, valdecoxib, rofecoxib, lumiracoxib, etoricoxib, parecoxib, 2-(3,4-difluorophenyl)-4-(3-hydroxy-3-methylbutoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone, and (S)-6,8-dichloro-2-(trifluoromethyl)-2H-1-benzopyran-3-carboxylic acid;
- and
- a calcium modulating agent selected from the group consisting of nimodipine, nicardipine, nifedipine, amolodipine, isradipine, diltiazem, verapamil, beprildil, gallopamil, flunarizine, and pimozide.
Dependencies are inferred from the claim text.